Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pediatric Rare Disease Voucher Program Faces Expiration

Executive Summary

Stakeholders push Congress to renew program, although 21st Century Cures route unlikely.

You may also be interested in...



Rare Pediatric Priority Review Voucher Program Seems Headed For Short-Term Renewal

Chair of the House Energy and Commerce Committee raises questions about the priority review voucher program’s value, suggesting another limited extension may be upcoming.

Priority Review Voucher Program For Rare Pediatric Diseases Extended As FDA Lowers Fee

Next fiscal year will be a good one to redeem a voucher, and probably to qualify for one as well.

Duchenne Surprise: Sarepta Prices Exondys 51 Below Expectations

It sparked at least one analyst to question how Sarepta came up with a price for FDA's first approved Duchenne muscular dystrophy treatment.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS119107

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel